2316 988

Cited 50 times in

18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma.

DC Field Value Language
dc.contributor.author강원준-
dc.contributor.author김도영-
dc.contributor.author김범경-
dc.contributor.author김자경-
dc.contributor.author박준용-
dc.contributor.author성진실-
dc.contributor.author안상훈-
dc.contributor.author이광훈-
dc.contributor.author이도연-
dc.contributor.author이종두-
dc.contributor.author한광협-
dc.date.accessioned2014-12-20T17:19:04Z-
dc.date.available2014-12-20T17:19:04Z-
dc.date.issued2011-
dc.identifier.issn0008-543X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/94372-
dc.description.abstractBACKGROUND: Metabolic activity assessed by (18)F-fluorodeoxyglocuse-positron emission tomography ((18)F-FDG-PET) reflects biological aggressiveness and prognoses in various tumors. The authors present a correlation between tumor metabolic activity and clinical outcomes in patients with hepatocellular carcinoma (HCC). METHODS: Over a 3-year period (2005-2008), 135 locally advanced HCC patients were treated with localized concurrent chemoradiotherapy (CCRT; external beam radiotherapy at 45 grays for 5 weeks plus concurrent hepatic arterial infusion of 5-fluorouracil during the first and fifth week) followed by repetitive hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin. Among them, the authors studied 107 who received (18)F-FDG-PET before CCRT. Maximal standardized uptake values (SUVs) of tumors were calculated. RESULTS: The median maximal tumor SUV was 6.1 (range, 2.4-∼19.2). Patients with low maximal tumor SUVs (<6.1) had a higher disease control rate than those with high maximal tumor SUVs (≥6.1) (86.8% vs 68.5%, respectively, P = .023). Both median progression-free survival (PFS; 8.4 vs 5.2 months; P = .003) and overall survival (OS; 17.9 vs 11.3 months; P = .013) were significantly longer in the low maximal tumor SUV group than in the high maximal tumor SUV group, respectively. In multivariate analysis, low maximal tumor SUV and objective responses to CCRT remained significant for PFS and OS. The high maximal tumor SUV group was more likely to have extrahepatic metastasis within 6 months than the low maximal tumor SUV group (58.1% vs 26.8%, respectively; P < .001). Similar results were obtained for the maximal tumor SUV/normal liver maximal SUV ratio (<2 vs ≥2) concerning progression, death, and extrahepatic metastasis. CONCLUSIONS: Metabolic activity may be useful not only in predicting prognosis and treatment responses, but also in establishing optimal treatment plans in locally advanced HCC.-
dc.description.statementOfResponsibilityopen-
dc.format.extent4779~4787-
dc.relation.isPartOfCANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAnalysis of Variance-
dc.subject.MESHCarcinoma,Hepatocellular/blood-
dc.subject.MESHCarcinoma,Hepatocellular/diagnostic imaging-
dc.subject.MESHCarcinoma,Hepatocellular/metabolism*-
dc.subject.MESHCarcinoma,Hepatocellular/pathology-
dc.subject.MESHCarcinoma,Hepatocellular/therapy*-
dc.subject.MESHChemoradiotherapy-
dc.subject.MESHCisplatin/administration & dosage-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHDrug Administration Schedule-
dc.subject.MESHFemale-
dc.subject.MESHFluorodeoxyglucose F18*-
dc.subject.MESHFluorouracil/administration & dosage-
dc.subject.MESHHepatic Artery-
dc.subject.MESHHumans-
dc.subject.MESHInfusions, Intra-Arterial-
dc.subject.MESHKaplan-Meier Estimate-
dc.subject.MESHLiver Neoplasms/blood-
dc.subject.MESHLiver Neoplasms/diagnostic imaging-
dc.subject.MESHLiver Neoplasms/metabolism*-
dc.subject.MESHLiver Neoplasms/pathology-
dc.subject.MESHLiver Neoplasms/therapy*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPositron-EmissionTomography*/methods-
dc.subject.MESHPredictive Value of Tests-
dc.subject.MESHPrognosis-
dc.subject.MESHRadiopharmaceuticals-
dc.subject.MESHRadiotherapy Dosage-
dc.subject.MESHResearch Design-
dc.subject.MESHTreatment Outcome-
dc.title18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorBeom Kyung Kim-
dc.contributor.googleauthorWon Jun Kang-
dc.contributor.googleauthorJa Kyung Kim-
dc.contributor.googleauthorJinsil Seong-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorDo Youn Lee-
dc.contributor.googleauthorKwang Hoon Lee-
dc.contributor.googleauthorJong Doo Lee-
dc.contributor.googleauthorKwang-Hyub Han-
dc.identifier.doi10.1002/cncr.26099-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00062-
dc.contributor.localIdA00487-
dc.contributor.localIdA00852-
dc.contributor.localIdA01675-
dc.contributor.localIdA01956-
dc.contributor.localIdA02226-
dc.contributor.localIdA02676-
dc.contributor.localIdA02718-
dc.contributor.localIdA03138-
dc.contributor.localIdA04268-
dc.contributor.localIdA00385-
dc.relation.journalcodeJ00434-
dc.identifier.eissn1097-0142-
dc.identifier.pmid21469082-
dc.subject.keywordhepatocellular carcinoma-
dc.subject.keywordfluorodeoxyglucose-
dc.subject.keywordstandardized uptake value-
dc.subject.keywordchemoradiotherapy-
dc.subject.keywordtumor response-
dc.subject.keywordsurvival-
dc.contributor.alternativeNameKang, Won Jun-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.alternativeNameKim, Beom Kyung-
dc.contributor.alternativeNameKim, Ja Kyung-
dc.contributor.alternativeNamePark, Jun Yong-
dc.contributor.alternativeNameSeong, Jin Sil-
dc.contributor.alternativeNameAhn, Sang Hoon-
dc.contributor.alternativeNameLee, Kwang Hun-
dc.contributor.alternativeNameLee, Do Yun-
dc.contributor.alternativeNameLee, Jong Doo-
dc.contributor.alternativeNameHan, Kwang Hyup-
dc.contributor.affiliatedAuthorKang, Won Jun-
dc.contributor.affiliatedAuthorKim, Beom Kyung-
dc.contributor.affiliatedAuthorKim, Ja Kyung-
dc.contributor.affiliatedAuthorPark, Jun Yong-
dc.contributor.affiliatedAuthorSeong, Jin Sil-
dc.contributor.affiliatedAuthorAhn, Sang Hoon-
dc.contributor.affiliatedAuthorLee, Kwang Hun-
dc.contributor.affiliatedAuthorLee, Do Yun-
dc.contributor.affiliatedAuthorLee, Jong Doo-
dc.contributor.affiliatedAuthorHan, Kwang Hyup-
dc.contributor.affiliatedAuthorKim, Do Young-
dc.rights.accessRightsfree-
dc.citation.volume117-
dc.citation.number20-
dc.citation.startPage4779-
dc.citation.endPage4787-
dc.identifier.bibliographicCitationCANCER, Vol.117(20) : 4779-4787, 2011-
dc.identifier.rimsid27576-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Nuclear Medicine (핵의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.